You are being redirected because this document is part of your ASTM Compass® subscription.
    This document is part of your ASTM Compass® subscription.


    The Clinical Evaluation of a Bioresorbable Minipin

    Published: 0

      Format Pages Price  
    PDF (432K) 16 $25   ADD TO CART
    Complete Source PDF (4.2M) 173 $83   ADD TO CART

    Cite this document

    X Add email address send
      .RIS For RefWorks, EndNote, ProCite, Reference Manager, Zoteo, and many others.   .DOCX For Microsoft Word


    The gradual shift from nonresorbable membranes to biodegradable and bioresorbable membranes represents one of the most significant trends in guided tissue regeneration (GTR) and guided bone regeneration (GBR) research. The clinical benefits of biodegradable and bioresorbable membranes that have the capacity to integrate with surrounding soft and hard tissues are a result of a more mechanically stable and therefore predictable wound healing environment. This biomechanical stability can be further enhanced by the stabilization of the physical barrier construct using additional fixation devices. Therefore, bioresorbable minipins have been desigened and fabricated. The minipins are made of poly (L-lactid-co-D, L-lactid) in a 7:3 ratio. The average molecular weight was measured at Mw 140 000, Mn 36 900, and Mw/Mn 3.7 respectively, with the intrinsic viscosity of 1.3 dl/g. The degradation and resorption kinetics as well as the biocompatibility of injection molded devices made of poly (L-lactid-co-D, L-lactid) 70/30 has already been evaluated in several in vitro and in vivo studies. Experimental as well as clinical evaluation of the bioresorbable minipin was performed. Mass loss of the minipin was initiated after 6 months and it was completely metabolized by the body after 9 to 12 months without a clinically detectable foreign body reaction.


    guided bone regeneration, membrane fixation and stabilization, bioresorbable minipins

    Author Information:

    Hutmacher, DW
    National University of Singapore,

    Kirsch, A

    Ackermann, KL

    Liedtke, H
    Boehringer Ingelheim, Ingelheim am Rhein,

    Hürzeler, MB
    Albert Ludwigs University, Freiburg,

    Committee/Subcommittee: F04.48

    DOI: 10.1520/STP15302S